CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading compound profile…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Cannabinoids/N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine

Endocannabinoids

N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine

An <em>N</em>-acylethanolamine 22:6 that is the ethanolamide of (4<i>Z</i>,7<i>Z</i>,10<i>Z</i>,13<i>Z</i>,16<i>Z</i>,19<i>Z</i>)-docosahexaenoic acid.

Definition: CHEBI:85252 · Chemical Entities of Biological Interest · release 253

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-hydroxyethyl)docosa-4,7,10,13,16,19-hexaenamideAnandamide (22:6, n-3)N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl ethanolamineN-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamineN-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-ethanolamineN-cis-4,7,10,13,16,19-docosahexanoylethanolamineSynaptamide

5public articles

0registered condition areas

All documents →

Identity & provenance

Chemical identity

C24H37NO2 · molecular weight 371.565

CHEBI: CHEBI:85252↗HMDB: hmdb:HMDB0013658↗INCHI: InChI=1S/C24H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-24(27)25-22-23-26/h3-4,6-7,9-10,12-13,15-16,18-19,26H,2,5,8,11,14,17,20-23H2,1H3,(H,25,27)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-↗INCHIKEY: GEEHOLRSGZPBSM-KUBAVDMBSA-N↗LIPIDMAPS: lipidmaps:LMFA08040009↗PUBCHEM_CID: 5283451↗PUBMED: pubmed:18227059↗REAXYS: reaxys:7653452↗

Sources: ChEBI · 253 PubChem computed properties · pug-13a37a0cb3ce2c21

0 referenced plant-occurrence records. They are identity candidates, not clinical evidence.

Research areas

Conditions found alongside this compound

Document links and organism occurrence are candidates, not proof of efficacy, safety or a treatment recommendation.

No published condition report is linked yet.

Linked local records

Medicines and registered studies

Links use source-reported active ingredients or study intervention names and remain candidates, not treatment claims.

Medicines with this active ingredient

No public medicine record matched.

Registered studies

0 exact source-intervention matches.

No registered study intervention matched.

Latest documents

Recent research

2021

N-docosahexaenoylethanolamine reduces neuroinflammation and cognitive impairment after mild traumatic brain injury in rats.

Scientific Reports · Free full text

2020

Biosynthesis of N-Docosahexanoylethanolamine from Unesterified Docosahexaenoic Acid and Docosahexaenoyl-Lysophosphatidylcholine in Neuronal Cells.

International Journal of Molecular Sciences · Free full text

2020

N-Docosahexaenoylethanolamine Attenuates Neuroinflammation and Improves Hippocampal Neurogenesis in Rats with Sciatic Nerve Chronic Constriction Injury.

Marine Drugs · Free full text

2016

N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling.

Journal of Neuroinflammation · Free full text

2016

Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function.

Nature Communications · Free full text

Ontology definitions normalize terms; they do not establish medical claims.